T-1101 Accepted for Poster Presentation at the 2025 European Society for Medical Oncology (ESMO) Congress, Highlighting Clinical Promise and Global Recognition
Taivex announced that the latest clinical trial results of its novel anticancer drug candidate T-1101 have been accepted for poster presentation at the 2025 European Society for Medical Oncology (ESMO) Congress. As Europe’s most influential oncology congress, ESMO features highly competitive abstract selection each year. The inclusion of T-1101 underscores its innovative mechanism and clinical …